American International Group Inc. increased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 16.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,094 shares of the company’s stock after buying an additional 3,638 shares during the quarter. American International Group Inc.’s holdings in Protagonist Therapeutics were worth $721,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of PTGX. Bank of New York Mellon Corp lifted its holdings in shares of Protagonist Therapeutics by 0.9% in the first quarter. Bank of New York Mellon Corp now owns 139,769 shares of the company’s stock valued at $3,310,000 after buying an additional 1,275 shares during the period. MetLife Investment Management LLC lifted its holdings in shares of Protagonist Therapeutics by 58.5% during the first quarter. MetLife Investment Management LLC now owns 23,914 shares of the company’s stock valued at $566,000 after purchasing an additional 8,826 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Protagonist Therapeutics by 5.6% during the first quarter. Rhumbline Advisers now owns 46,426 shares of the company’s stock valued at $1,099,000 after purchasing an additional 2,457 shares during the last quarter. Lord Abbett & CO. LLC lifted its holdings in shares of Protagonist Therapeutics by 68.5% during the first quarter. Lord Abbett & CO. LLC now owns 275,787 shares of the company’s stock valued at $6,531,000 after purchasing an additional 112,123 shares during the last quarter. Finally, First Trust Advisors LP purchased a new stake in shares of Protagonist Therapeutics during the first quarter valued at $989,000. Institutional investors and hedge funds own 98.63% of the company’s stock.
Protagonist Therapeutics Trading Down 1.0 %
Shares of Protagonist Therapeutics stock opened at $16.12 on Friday. The stock has a 50-day moving average price of $16.19 and a 200 day moving average price of $20.77. The company has a market cap of $929.80 million, a P/E ratio of -6.15 and a beta of 1.85. Protagonist Therapeutics, Inc. has a 1 year low of $7.24 and a 1 year high of $30.10.
Analyst Ratings Changes
About Protagonist Therapeutics
Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease.
- Five stocks we like better than Protagonist Therapeutics
- How to Invest in the Healthcare Sector
- Amazon, Target, Walmart in a race for fastest delivery
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Palo Alto Networks: the one security stock to rule them all
- Investing in Construction Stocks
- Is it time to buy the dip in Walmart shares?
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.